ABSTRACT
Background Sepsis, a life-threatening disorder with multi-organ dysfunction, is a leading cause of neonatal mortality. Current microbiology-based sepsis diagnosis is time-consuming, and identification of deregulated host serum metabolite signatures might be useful to develop early screening tools and host-directed therapeutics.
Methods In this multi-institutional study, 500 neonates (41.2% female) were classified to culture-positive (CP) or negative sepsis (CN) cases and controls (no sepsis: NS, healthy control: HC) based on their microbial culture and mass spectrometry test results. The neonates were randomly grouped into two discovery sets (I:n=71; II:n=269), a validation set (n=60), and a longitudinally followed-up population (n=100). Serum samples of these neonates were processed and profiled using gas chromatography coupled to either quadrupole or time-of-flight mass spectrometry (GC-MS/-TOF-MS). Deregulated (log2case/control ≥±0.58, p<0.05) serum metabolites in sepsis cases were identified from the discovery sets and their predictive accuracy in the validation set was calculated using area under the receiving operator characteristic curve (AUC of ROC). The abundance of these deregulated metabolites was monitored in the longitudinally followed-up neonates (CP:n=29, CN:n=35, and NS:n=36) completing therapeutic intervention.
Results Most of the CP cases were Klebsiella pneumoniae (28.6%) or Acinetobacter baumannii (20.6%) positive. Gestational age (CP: 30.9±1.9 weeks, CN: 30.9±1.8 weeks, HC: 32.3±1.3 weeks, NS: 31.6±1.5 weeks) and birthweight (CP: 1.4±0.3 kg, CN: 1.4±0.4 kg, HC: 1.7±0.3 kg, NS: 1.6±0.3 kg) were lower in sepsis neonates compared to controls. Out of 57 identified serum metabolites, a set of six (1,5-Anhydro-D-sorbitol-Lactic-acid-Malic-acid-Myo-inositol-Phenylalanine-Lysine) were identified as sepsis biosignature. The AUC of ROC of the biosignature to predict CP or CN from HC was 0.97 and from NS was 0.84 and 0.64, respectively. Myo-inositol, malic acid, and 1,5-anhydro-D-sorbitol revert to the HC levels in neonates completing therapeutic intervention.
Conclusions A serum metabolite signature showed a >97% predictive accuracy for sepsis and could be further explored for its diagnostic and host-directed therapeutic potential.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by the Department of Biotechnology (DBT), Government of India.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Institutional Ethics Committee of International Centre for Genetic Engineering and Biotechnology, New Delhi, gave ethical approval for this work (ICGEB/IEC/2021/28, version 2). The Institutional Ethics Committee of All India Institute of Medical Sciences, New Delhi, gave ethical approval for this work (IEC-1074/06.11.20, RP-28/2020). The Institutional Ethics Committee of Vardhman Mahavir Medical College (VMMC) and Safdarjung Hospital, New Delhi, gave ethical approval for this work (IEC/VMMC/SJH/Project/2021-05/CC-157, dated 24.07.2021). The Institutional Ethics Committee of Dr. Baba Saheb Ambedkar Medical College and Hospital, New Delhi, gave ethical approval for this work (5(32)/2020/BSAH/DNB/PF, dated 31.08.2020). The Institutional Ethics Committee of Lady Hardinge Medical College, New Delhi, gave ethical approval for this work (LHMC/IEC/2022/03/30). The Institutional Ethics Committee of the University College of Medical Sciences & Guru Teg Bahadur Hospital, New Delhi, gave ethical approval for this work (IECHC-2022-51-R1, dated 07.12.2022).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
The manuscript has been revised to update the results obtained using a bigger discovery set and an independent validation and follow-up set. We increased the total number of neonates to 500 and detected six deregulated metabolites (1,5-anhydro-D-sorbitol, phenylalanine, lysine, myo-inositol, lactic acid, and malic acid). Our discovery set included 340 neonates and the detected deregulated metabolites were validated in an independent data set (n=60) using the area under the receiver operating curve (AUC of ROC). We also recorded the levels of the deregulated metabolites in longitudinally followed-up neonates upon treatment and recovery (n=100) and observed that their levels decreased upon recovery.
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
